Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Hall effect in bilayer graphene and shown that this ... electric field. , The fractional quantum Hall effect, ... are exposed to large magnetic fields, is a striking ... behave as a single system. However, while the basic ... of this collective behavior remain not well understood, in ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
Breaking Biology Technology:Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Layered security: Carbon nanotubes promise improved flame-resistant coating 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3
... Disease Altering Treatment Shows Ability to Prevent HIV ... VIRxSYS Corporation, a,privately held company developing gene therapies ... Phase II trial of VRX496, a gene,therapy for ... Conference on,Retroviruses and Opportunistic Infections (CROI) in Boston, ...
... Strengthening PPD,s presence in Eastern Europe, WILMINGTON, N.C., ... has signed an agreement to purchase InnoPharm,Ltd., an independent ... acquisition will expand PPD,s global reach with,established offices in ... CROs in Russia, InnoPharm was a pioneer in the,implementation ...
... (Nasdaq: IDIX ) announced today that Idenix management,will ... & Investor,Conference on Tuesday, February 12, 2008 at 9:30 ... the Waldorf-Astoria Hotel in New York, NY., The ... accessed,under "Calendar of Events" in the Idenix Investor Center ...
Cached Biology Technology:VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2PPD to Acquire InnoPharm Ltd. 2PPD to Acquire InnoPharm Ltd. 3
(Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family ... in the family rely on bees for their pollination. Only ... or vertebrates. The flowers of Axinaea appear in ... petals of the different species are pink, yellow, orange or ... the contrasting colours of their bulbous appendages. The pollination mechanism ...
(Date:7/10/2014)... has helped stabilize or even improve the state ... the situation in the Mediterranean has deteriorated over ... evaluating nine fish species reported in the Cell ... 10, scientists call for stringent monitoring of Mediterranean ... advanced management plans in Mediterranean waters. , Their ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5Novel type of bird pollination mechanism discovered in South America 2Mediterranean fish stocks show steady decline 2
... 20, 2013 Market news updates for advancing ... Inc. (OTCQB: NXTD), Apple Inc. (NASDAQ: AAPL ), ... CSCO ) and NQ Mobile Inc. (NYSE: NQ) ... published a report on NXT-ID, Inc., (OTCQB: NXTD) featuring the ...
... of all humans are persistently colonized with Staphylococcus aureus ... of the major sources of hospital-acquired infections, including the antibiotic-resistant ... discovered one of the keys to the immense success of ... immune defense mechanism and use it to destroy white blood ...
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
Cached Biology News:Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 2Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 3Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 4Biometric-Mobile Wallet Technology Takes Aims at a Target Market Of Nearly $1Billion Potential 5Staphylococcus aureus bacteria turns immune system against itself 2Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 2
...
... Antibody Validation Service enables early selection ... development by providing quantitative data for ... of each antibody. Furthermore quantitative antibody ... off-target activity of your antibodies., The ...
... western blotting. Get results sooner and save hours ... detection. Eliminates the need for a membrane transfer ... reagents are ready-to-use. No reagents to prepare or ... reagents required. Guarantees a simple to perform, mistake-free ...
... paper sandwiches are composed of a precut ... thick filter paper that are preassembled into ... These 7 x 8.5 cm membrane sandwiches ... Gel-sized gels and are supplied as a ...
Biology Products: